keyword
MENU ▼
Read by QxMD icon Read
search

carboplatin hypersensitivity reaction

keyword
https://www.readbyqxmd.com/read/28664179/the-tell-tale-heart-a-case-of-recurrent-vulvar-carcinoma-with-cardiac-metastasis-and-review-of-literature
#1
Syed Imran Mustafa Jafri, Naveed Ali, Salman Farhat, Faizan Malik, Mark Shahin
A 50-year-old female was diagnosed with vulvar cancer treated with left partial vulvectomy and bilateral lymphadenectomy. Ten months after her surgery, she presented with increased labial swelling, pain and discharge. Biopsy confirmed recurrence of squamous cell vulvar carcinoma. Incidentally, on restaging radiographic scans, she was found to have a large right ventricular mass which, after surgical debulking, was shown to be a squamous cell cancer of vulvar origin. She was commenced on chemotherapy with carboplatin and paclitaxel along with concurrent radiation therapy...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28622171/reactions-to-cytostatic-agents-in-children
#2
Josefina R Cernadas
PURPOSE OF REVIEW: The current review will focus on drug hypersensitivity reactions to chemotherapy specifically to those drugs most used in children. We know that potentially all chemotherapeutic agents can cause infusion reactions, generally defined as adverse drug reactions. Of these, some are Type A, defined as expected and described in the characteristics of the drug and others, and Type B, defined as unexpected reactions which cannot be explained by the known toxicity profile of the drug...
August 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28541630/universal-tolerance-of-nab-paclitaxel-for-gynecologic-malignancies-in-patients-with-prior-taxane-hypersensitivity-reactions
#3
Kathryn Maurer, Chad Michener, Haider Mahdi, Peter G Rose
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indication for nab-paclitaxel, dosing, response, toxicities including any HSR, and reason for discontinuation of nab-paclitaxel therapy. RESULTS: We identified 37 patients with gynecologic malignancies with a history of paclitaxel HSR who received nab-paclitaxel...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28446876/hypersensitivity-to-carboplatin-in-children-with-malignancy
#4
REVIEW
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Giorgio Attinà, Riccardo Riccardi
Purpose: Carboplatin-based regimens have proven efficacy in children with cancer. However, the development of hypersensitivity reactions (HSRs) may have a negative impact on treatment intensity and patients' outcome. The aim of this review is to summarize the incidence and the clinical features of HSRs occurring in children with cancer treated with carboplatin and their impact on treatment efficacy. Methods: Data were collected by searching for relevant studies on the incidence, clinical features and management of possible side effects about the use of carboplatin in children, published from March 1987 to October 2016 in the PubMed database...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28439238/rechallenge-to-carboplatin-in-children-with-low-grade-glioma-and-carboplatin-hypersensitivity-reactions
#5
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà, Riccardo Riccardi
Background: Carboplatin based regimens have demonstrated activity in pediatric patients with low grade gliomas (LGG). However, carboplatin hypersensitivity reactions (CHRs) may be a major problem leading to premature cessation of an effective therapy. The objectives of this study were to describe the prevalence, characteristics and management of CHR. Methods: We performed a retrospective review of children with LGG treated between January 1994 and July 2015 with carboplatin and vincristine who had a documented CHR...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28345825/comparison-of-hypersensitivity-reactions-to-carboplatin-retreatment-in-gynecologic-cancer-patients-between-one-and-two-hour-infusions-a-randomized-trial-study
#6
Weerawich Pornwattanakrilert, Prapaporn Suprasert
Objective: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. Setting: A Prospective Randomized Controlled Trial. Methods: Recurrent gynecologic cancer patients 25 to 80-years of age who were scheduled to receive carboplatin retreatment after previously receiving at least six cycles of carboplatin without a history of platinum allergy were invited to enroll. They were randomized to receive either a one-hour or two-hour carboplatin infusion in each cycle...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28124284/incidence-of-and-risk-factors-associated-with-nedaplatin-related-hypersensitivity-reactions
#7
Yuki Kawarada, Masayuki Miyazaki, Ayaka Itoh, Risa Araki, Hidetaka Iwamizu, Tomomi Kataoka, Yasuo Kumakura, Akiko Ota, Taku Nagai, Kiyofumi Yamada
BACKGROUND: Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of NDP-HSRs and the associated risk factors remain unclear. METHODS: We retrospectively examined patients who received NDP monotherapy between April 2011 and July 2015 in Nagoya University Hospital. HSRs severity was defined according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE ver...
January 25, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28094039/cisplatin-can-be-safely-administered-to-ovarian-cancer-patients-with-hypersensitivity-to-carboplatin
#8
A Bergamini, C Pisano, M Di Napoli, L Arenare, C Della Pepa, R Tambaro, G Facchini, P Gargiulo, S Rossetti, G Mangili, S Pignata, S C Cecere
OBJECTIVE: Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27916065/-clinical-analysis-of-hypersensitivity-reaction-of-platinum-in-ovarian-cancer-and-cervical-cancer-patients
#9
L Li, M Wu, J X Yang, X R Wan, H F Huang, L Y Pan, K Shen, J H Lang, Y Xiang
Objective: To investigate the incidence, risk factors, management and prognosis of hypersensitivity reaction (HSR) of platinum-based chemotherapy in patients of ovarian cancer and cervical cancer. Methods: Cases from Peking Union Medical College Hospital from Jan. 2013 to Jan. 2016 were checked for patients' data of epithelial ovarian cancer treated with carboplatin/paclitaxel (every 3 weeks) and patients of cervical cancer treated with concurrent radiochemotherapy using cisplatin (every week). General characters, pathological features, treatment and prognosis of patients were analyzed to determine the severity, symptoms, outcomes and risk factors of HSR...
November 25, 2016: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/27856924/prevention-of-carboplatin-induced-hypersensitivity-reactions-in-women-with-ovarian-cancer
#10
Katarzyna J Jerzak, Shaidah Deghan Manshadi, Pamela Ng, Manjula Maganti, Jeanna M McCuaig, Marcus Bulter, Amit Oza, Helen J Mackay
BACKGROUND: Carboplatin-based chemotherapy offers high response rates and improved overall survival for women with epithelial ovarian cancer, but its use is limited by the occurrence of hypersensitivity reactions. To evaluate the efficacy of prophylactic diphenhydramine for hypersensitivity reaction prevention, we reviewed the incidence of hypersensitivity reactions and identified patients at high risk of hypersensitivity reactions. METHODS: Women receiving ≥6 cycles of carboplatin-based chemotherapy for epithelial ovarian cancer were identified from our institutional database at the Princess Margaret Cancer Centre...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27789084/platinum-desensitization-in-patients-with-carboplatin-hypersensitivity-a-single-institution-retrospective-study
#11
Gary Altwerger, Gregory M Gressel, Diana P English, Wendelin K Nelson, Nina Carusillo, Dan-Arin Silasi, Masoud Azodi, Alessandro Santin, Peter E Schwartz, Elena S Ratner
OBJECTIVES: The carboplatin desensitization (CD) protocol presented here allows patients with either a positive skin test or a prior hypersensitivity reaction (HSR) to safely, rapidly and effectively continue with carboplatin infusions. Newly described factors can identify patients at risk for developing adverse events during CD. METHODS: A retrospective review was performed on patients with gynecologic cancer who underwent CD between 2005 and 2014. The CD protocol uses a four-step dilution process over 3...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27641482/extended-carboplatin-infusion-does-not-reduce-frequency-of-hypersensitivity-reaction-at-initiation-of-retreatment-in-patients-with-recurrent-platinum-sensitive-ovarian-cancer
#12
Timothy Lax, Don S Dizon, Michael Birrer, Aidan Long, Marcela Del Carmen, Annekathryn Goodman, Carolyn Krasner, Richard T Penson, Whitfield Growdon, Carlos A Camargo, Aleena Banerji
No abstract text is available yet for this article.
September 15, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27221832/clinical-features-of-oxaliplatin-induced-hypersensitivity-reactions-and-therapeutic-approaches
#13
REVIEW
Nusrat Bano, Rahila Najam, Faaiza Qazi, Ahmed Mateen
Oxaliplatin, a third generation novel platinum compound is the most effective first line chemotherapeutic agent for colorectal cancer (CRC) in combination with 5FU and leucovorin. It is indicated for pancreatic, gastric and testicular cancers combined with bevacuzimab, capecitabine, irinotecan and other cytotoxic agents. However, moderate to severe hypersensitivity reactions (HSR) during or after oxaliplatin infusion usually require cessation of chemotherapy or substitution of the key therapeutic drug which largely interferes with improved patient prognosis...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/27196693/effect-of-prophylactic-extended-infusion-carboplatin-on-incidence-of-hypersensitivity-reactions-in-patients-with-ovarian-fallopian-tube-or-peritoneal-carcinomas
#14
Amy L Pasternak, Nicholas A Link, Carolyn M Richardson, Peter G Rose
STUDY OBJECTIVE: To determine whether extended-infusion carboplatin, initiated at approximately the eighth cumulative carboplatin cycle and prior to development of carboplatin hypersensitivity, reduces the incidence of carboplatin hypersensitivity reactions in patients with ovarian, fallopian tube, or peritoneal cancer. DESIGN: Retrospective chart review. SETTING: Large integrated health system. PATIENTS: A total of 326 patients with ovarian, fallopian tube, or primary peritoneal cancer who received at least eight cumulative cycles of carboplatin between January 2007 and September 2014 were included...
July 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27181615/clinical-utility-of-basophil-cd203c-as-a-biomarker-for-predicting-the-timing-of-hypersensitivity-reaction-in-carboplatin-rechallenge-three-case-reports
#15
Takuya Iwamoto, Hiroko Sugimoto, Tsutomu Tabata, Masahiro Okuda
PURPOSE: Drug desensitization has been found to be an effective option for carboplatin rechallenge in patients at risk for severe hypersensitivity reaction. However, identifying such patients requires precise clinical tests. This study was performed to evaluate the clinical utility of basophil CD203c to predict the timing of carboplatin-induced severe hypersensitivity reaction. METHODS: Here we report on 3 patients undergoing a carboplatin-desensitization protocol at Mie University Hospital...
June 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27098551/intravenous-versus-oral-dexamethasone-for-prophylaxis-of-paclitaxel-associated-hypersensitivity-reaction-in-patients-with-primary-ovarian-fallopian-tube-and-peritoneal-cancer-a-double-blind-randomized-controlled-trial
#16
RANDOMIZED CONTROLLED TRIAL
Marut Yanaranop, Surasith Chaithongwongwatthana
AIM: To compare the efficacies and side effects of intravenous and oral dexamethasone (IV-D and PO-D) for paclitaxel-associated hypersensitivity reaction (P-HSR) prophylaxis in patients with primary ovarian, fallopian tube and peritoneal carcinomas (POC/PFTC/PPC) receiving a first cycle of paclitaxel plus carboplatin (TC). METHODS: In this double-blind randomized controlled trial, patients with POC/PFTC/PPC receiving a first cycle of TC were randomly allocated in a 1:1 ratio to either the IV-D or PO-D groups...
September 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/26990212/adjunct-histamine-blockers-as-premedications-to-prevent-carboplatin-hypersensitivity-reactions
#17
Claire M Mach, Elisabeth A Lapp, Kellie J Weddle, Rodney J Hunter, Kimberly A Burns, Crystal Parker, Jubilee Brown, Judith A Smith
OBJECTIVE: The objective of this study was to evaluate the impact of premedications given as an adjunct to carboplatin on the incidence of hypersensitivity reactions in women with ovarian cancer. Medications of interest include a histamine1 (H1 ) and histamine2 (H2 ) blocker in addition to dexamethasone. METHODS: This was a retrospective chart review evaluating the addition of an H1 and H2 blocker in addition to dexamethasone as standard premedications on the incidence of carboplatin hypersensitivity reactions (CHRs) in women with ovarian cancer...
May 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/26895621/safety-costs-and-efficacy-of-rapid-drug-desensitizations-to-chemotherapy-and-monoclonal-antibodies
#18
David Sloane, Usha Govindarajulu, Jacob Harrow-Mortelliti, William Barry, Florence Ida Hsu, David Hong, Tanya Laidlaw, Ross Palis, Henry Legere, Supinda Bunyavanich, Rebecca Breslow, Duane Wesemann, Nora Barrett, Patrick Brennan, Hey Jin Chong, Anne Liu, James Fernandez, Laura Fanning, Timothy Kyin, Katherine Cahill, Lora Bankova, Ashly Lynch, Suzanne Berlin, Susana Campos, Charles Fuchs, Robert Mayer, Ursula Matulonis, Mariana Castells
BACKGROUND: Rapid drug desensitization (RDD) is used to address hypersensitivity reactions to chemotherapeutics and monoclonal antibodies, allowing patients to be treated with optimal pharmacological agents. RDD protocols are tailored to each individual patient's reaction and needs, and protect against anaphylaxis, but overall risks, costs, and benefits have not been determined. OBJECTIVE: We investigated the safety, efficacy, costs, and life expectancy of patients in a large population undergoing RDD...
May 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/26854461/hypersensitivity-reactions-to-platinum-derivatives-findings-of-new-predictive-markers
#19
Sinziana Cetean, Tudor Ciuleanu, Daniel-Corneliu Leucuta, Calin Cainap, Anne-Marie Constantin, Irina Cazacu, Simona Cainap, Alexandra Gherman, Luminita Oprean, Adriana Hangan, Radu Oprean
PURPOSE: Platinum derivatives play a very important role in cancer therapy. Despite their outstanding results in the treatment of tumors with different locations, the occurrence of hypersensitivity reactions raises issues when it comes to therapy decision, because the changing of chemotherapy line could influence the tumor's evolution. Over the years the scientific community has paid particular attention to the mechanism by which this occurs and to identification of predictive factors...
November 2015: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/26759527/limitations-to-the-use-of-carboplatin-based-therapy-in-advanced-ovarian-cancer
#20
Christina Fotopoulou
Most patients with recurrent ovarian cancer (ROC) undergo a series of remissions and recurrences, therefore the additive or cumulative toxicity of chemotherapy must be factored into their treatment plan. There are challenges in defining tailored therapeutic approaches, including optimal timing and drug sequencing management strategies to treat patients with ROC. This is particularly relevant as new cytotoxic drugs and biological agents become available. Many of these drugs are associated with increased toxicity and with no observable survival advantage...
December 2014: EJC Supplements: EJC
keyword
keyword
114338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"